Trisha Pasricha
Trisha Pasricha is a physician and researcher working in the field of gastroenterology and neurogastroenterology. Her published research focuses on disorders of gut-brain interaction, motility disorders like irritable bowel syndrome, and gastrointestinal manifestations related to Parkinson's disease. She has also investigated clinical topics such as GLP-1 receptor agonists, endoscopic interventions, and behavioral risk factors for digestive health issues.
28 claims checked on air: 4 context 2 contradicted 18 supported 4 unverified
What they said on air
1 citing their own research
Approximately one in three people in the UK avoid discussing bowel symptoms with their doctor due to embarrassment.
"there's this statistic that about one in three people--this came from the UK--one in three people will avoid talking to their doctor about their bowel symptoms because they're so embarrassed." (said at 0:06:44)
No published record matching the claim that approximately one in three people in the UK avoid discussing bowel symptoms with their doctor due to embarrassment was located; this does not prove the claim false. While embarrassment is widely documented as a substantial barrier to medical help-seeking for gastrointestinal and colorectal symptoms in qualitative and survey literature, peer-reviewed epidemiological data quantifying this exact one-in-three proportion were not identified, suggesting the figure likely derives from unindexed charity or public opinion polling reports.
Forty percent of Americans experience bowel habits that disrupt their daily lives.
"they fall into that 40% of Americans whose bowel habits disrupt their daily lives." (said at 0:09:08)
Large population-based survey data in the United States demonstrate a high overall burden of gastrointestinal (GI) symptoms, with 61% of surveyed Americans reporting at least one GI symptom in the past week. Individual bowel-specific symptoms such as diarrhea and constipation were reported by approximately 20.2% and 19.7% of respondents, respectively. While gastrointestinal symptoms broadly affect a majority of the US population, citing a specific 40% figure for bowel habits that disrupt daily life requires context, as it approximates broader estimates of overall functional gastrointestinal disorders or combined symptom burdens rather than a single specific metric for life-disrupting bowel habits.
Colorectal cancer is the leading cause of cancer mortality among younger people.
"Colorectal cancer is leading the way right now, as of 2026, in terms of early onset colorectal cancers and mortality for younger people when it comes to different kinds of cancers." (said at 0:09:55)
According to surveillance data from the American Cancer Society published in CA: A Cancer Journal for Clinicians (2024), colorectal cancer has risen to become the leading cause of cancer mortality among men under age 50 in the United States (up from the fourth-leading cause in the late 1990s). However, among women under age 50, colorectal cancer is the second-leading cause of cancer death, following breast cancer.
Colorectal cancer complication and mortality rates are declining among older individuals.
"And what's, in a way, good news is that for older people, the complications, the death rates, those are actually declining. The rates are getting a little bit better as you're older, but they're not so much for that younger group." (said at 0:10:12)
Surveillance data from national cancer registries and health statistics confirm that colorectal cancer (CRC) mortality rates have steadily declined among older adults (particularly those aged 65 years and older, decreasing by approximately 2% to 3% annually), largely attributable to screening, early detection, and improved treatments. In contrast, CRC mortality and incidence have been rising among adults under age 50.
- supports: Colorectal cancer statistics, 2026. (CA: a cancer journal for clinicians 2026) · cited 34x in the literature
"Mortality has increased in adults younger than 50 years by 1% annually since 2004, whereas rates have decreased in adults 65 years and older by 2.3% annually since 2012." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Trends in colorectal cancer mortality among younger versus older adults in 49 countries. (Journal of the National Cancer Institute 2026)
"In half of the countries with increasing trends, rates in older adults (50 to 79 years) were stable (Colombia, Philippines, Croatia [women only]) or decreasing (Uruguay, the U.K., Australia, Canada, the U.S., Argentina)." (abstract, results, passage verified)
pubmedfull study (doi)
According to a study from the Colorectal Cancer Alliance, one third of people defer their colonoscopy due to embarrassment about the procedure.
"A third of people, this is a study that came from the Colorectal Cancer Alliance, a third of people will defer their whole colonoscopy because they're so embarrassed by the procedure." (said at 0:11:13)
No published record matching the claim that a study from the Colorectal Cancer Alliance found one-third of people defer colonoscopy specifically due to embarrassment was located; this does not prove the claim false.
The recommended starting age for routine colorectal cancer screening in average-risk individuals was lowered from 50 to 45 years.
"It actually was somewhat recently, within the last couple of years, that we moved it from 50 as the starting age to now it is 45." (said at 0:12:55)
Major guidelines updated the recommended starting age for routine colorectal cancer screening in average-risk adults from 50 to 45 years. In 2021, the US Preventive Services Task Force (USPSTF) officially expanded its recommendation statement to include screening in adults aged 45 to 49 years (Grade B recommendation) alongside adults aged 50 to 75 years (Grade A recommendation), driven by rising incidence rates of early-onset colorectal cancer and simulation modeling demonstrating moderate net benefit.
Only about 20% of eligible adults aged 45 to 49 are actually obtaining screening colonoscopies.
"even for those people who are that 45 to 49-year range, who have been eligible for colorectal cancer screening for several years, only about 20% of them are actually getting their colonoscopies." (said at 0:13:11)
The claim that roughly 20% of adults aged 45 to 49 are obtaining colorectal cancer screening reflects baseline screening adherence rates immediately following the 2021 USPSTF guideline update (which lowered the recommended starting age from 50 to 45). In 2021, screening rates in this age group were documented at approximately 20% to 25.6%. However, screening uptake in this population has grown since then, reaching 31% to 36% nationally in 2023 and exceeding 50% in some regional health systems. Furthermore, these overall screening rates encompass both colonoscopies and stool-based modalities (such as FIT and FIT-DNA), rather than colonoscopies alone.
- context: Colorectal Cancer Test Completion among Adults Aged 45 to 75 in an Integrated Healthcare S… (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2026)
"Colorectal cancer test completion increased from 61.8% (2021) to 70.8% (2024), with the largest increase in the 45- to 49-year age group (25.6% to 51.7%)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Low colorectal cancer screening among adults aged 45-49 years in the US, 2023. (The American journal of managed care 2026)
"The rate of CRC screening was significantly lower among adults aged 45 to 49 years than among adults aged 50 to 54 years (36.1% vs 55.6%; P < .001)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Colorectal Cancer Screening and Health-Related Social Needs in a National Sample of US Adu… (JAMA network open 2026) · cited 1x in the literature
"The proportion up to date with CRC screening was 63.91% (9758 adults) overall and increased with age, from 31.01% (586 adults) among adults aged 45 to 49 years to 64.24% (4539 adults) among those aged 50 to 64 years" (abstract, results, passage verified)
pubmedfull study (doi) - context: Colorectal Cancer Screening Uptake Across Age Groups in an Academic Health System. (American journal of preventive medicine 2026)
"Adults aged 45-49 years experienced increased screening adherence from 20% in 2021 to 46% in 2023." (abstract, results, passage verified)
pubmedfull study (doi)
A quarter of early-onset colorectal cancer cases could have been detected earlier with age-appropriate screening based on family risk.
"there actually is a big chunk of people that we--a quarter of cases that were younger could have been caught earlier if they had just gotten age-appropriate screening according to their own family risk." (said at 0:14:05)
No published record matching the specific claim that approximately a quarter of early-onset colorectal cancer cases could have been detected earlier through age-appropriate screening based on family history guidelines was located; this does not prove the claim false.
Colonic polyps have an approximate 10% rate of conversion to cancer.
"It's not cancer yet, but it's on that path that you know, there's like a 10% conversion rate to cancer for these polyps." (said at 0:17:50)
No published record matching the specific claim that colonic polyps have an approximate 10% rate of conversion to cancer was located; this does not prove the claim false.
Acute stressful thoughts evoking fear or anxiety cause stomach motility to slow down while simultaneously speeding up colonic motility.
"having these thoughts that felt stressful, evoked fear, evoked anxiety, could cause both the stomach to slow down, and this is something that I study, the stomach to slow down and not contract at the regular rhythm that it should, but simultaneously it caused the colon to speed up and rev up." (said at 0:26:40)
Extensive physiological research in both humans and animal models demonstrates that acute psychological stress, fear, and anxiety alter gastrointestinal motility in a dual pattern: inhibiting gastric contractions and delaying gastric emptying while simultaneously stimulating colonic transit and motor activity. This response is centrally coordinated through the brain-gut axis and the autonomic nervous system, largely mediated by central corticotropin-releasing factor (CRF) signaling.
The enteric nervous system contains a network of millions of neurons embedded within the muscular layers of the gastrointestinal tract.
"That's the brain of the gut. It has a network of millions of neurons that are living, but it's buried in the muscle layer." (said at 0:28:44)
The statement accurately reflects established human gastrointestinal anatomy and neurobiology. The enteric nervous system (ENS), frequently referred to as the 'brain of the gut' or 'second brain,' contains an estimated 200 to 500+ million neurons organized into interconnected plexuses—most notably the myenteric (Auerbach's) plexus, which resides embedded between the longitudinal and circular muscle layers of the digestive tract wall.
- supports: Unexpected Roles for the Second Brain: Enteric Nervous System as Master Regulator of Bowel… (Annual review of physiology 2019) · cited 252x in the literature
"To successfully coordinate this complex array of functions, the bowel relies on the enteric nervous system (ENS), an intricate network of more than 500 million neurons and supporting glia that are organized into distinct layers or plexi within the bowel wall." (abstract, background, passage verified)
pubmedfull study (doi) - supports: The Imperative for Innovative Enteric Nervous System-Intestinal Organoid Co-Culture Models… (Cells 2024) · cited 18x in the literature
"Referred to as the "second brain", the ENS orchestrates pivotal roles in GI functions, including motility, blood flow, and secretion. The ENS is organized into myenteric and submucosal plexuses." (abstract, background, passage verified)
pubmedfull study (doi)
In irritable bowel syndrome (IBS), enteric nervous system nerves fire at a lower threshold and there is an increased concentration of pain-signaling TRPV1 receptors in the colon.
"We know that the nerves in the enteric nervous system will be triggered at a lower threshold, that there'll be a higher concentration of TRPV1 receptors in the colon, which is a receptor that signals pain to the brain." (said at 0:29:45)
Clinical tissue biopsy studies confirm that patients with irritable bowel syndrome (IBS) have a significantly higher density of transient receptor potential vanilloid type 1 (TRPV1) receptor-expressing sensory nerve fibers in colonic biopsies compared to controls. This increased expression correlates with abdominal pain severity and visceral hypersensitivity, which lowers the stimulus threshold required to trigger pain signals sent to the central nervous system.
Psychological stress, such as defending a college thesis during an oral examination, rapidly increases intestinal permeability, anxiety, and cortisol levels.
"And so, there was a group of students who had to like defend their college thesis in front of this panel of judges. And they measured their intestinal permeability in the moments leading up to having to give that oral exam and then afterwards. And they found, of course, that their levels of stress went up, their anxiety went up, their cortisol went up. And then, so too did their intestinal permeability." (said at 0:32:24)
A 2014 human experimental study investigated the effect of acute psychological stress—specifically a public speaking task in front of an audience/evaluators (the Trier Social Stress Test paradigm)—on small intestinal permeability quantified via a 2-hour urinary lactulose-mannitol excretion test. The study demonstrated that public speech stress significantly increased salivary cortisol and small intestinal permeability compared to control conditions. Subgroup analysis confirmed that the increase in intestinal permeability was specifically present in subjects exhibiting a significant cortisol elevation.
Ultra-processed foods, alcohol, and poor sleep have been shown to increase intestinal permeability.
"ultra-processed foods have been studied to increase intestinal permeability, alcohol, poor sleep, all of the things that are actually like quite boring. You've heard from your doctor a million times. All of those things do modulate your permeability" (said at 0:34:03)
Scientific literature supports the claim that ultra-processed foods, alcohol consumption, and sleep deprivation alter and increase intestinal permeability. Consuming ultra-processed foods is associated with gut barrier dysfunction, dysbiosis, and increased intestinal permeability. Chronic and acute alcohol consumption disrupts intestinal mucosal integrity and tight junctions, promoting intestinal barrier breakdown. Similarly, experimental sleep deprivation studies demonstrate marked increases in gut permeability and structural damage to the intestinal epithelial barrier.
- supports: Stellate ganglion block attenuates gut barrier injury in sleep-deprived rats in a gut micr… (Scientific reports 2026)
"Evans blue staining showed that intestinal permeability was significantly increased after 7 days of SD, reaching approximately fourfold higher levels compared with the control (CON) group (p < 0.0001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Gut-Liver Axis Dysfunction in Alcohol-Associated Liver Disease and the Potential Role of S… (Nutrients 2026)
"Alcohol-associated liver disease (ALD) is driven by gut-liver axis dysfunction, including intestinal barrier disruption, dysbiosis, microbial translocation, inflammation, metabolic dysfunction, and malnutrition." (abstract, background/objectives, passage verified)
pubmedfull study (doi) - supports: Ultra-Processed Foods and Metabolic Dysfunction: Mechanisms, Clinical Implications, and Pu… (Current nutrition reports 2026)
"Proposed mechanisms include gut microbiota alterations, increased intestinal permeability, mitochondrial dysfunction, oxidative stress, impaired metabolic flexibility, and chronic low-grade inflammation." (abstract, results, passage verified)
pubmedfull study (doi)
Marathon runners are well described to have high amounts of intestinal permeability.
"marathon runners are like really well described to have high amounts of intestinal permeability, not always a good thing." (said at 0:44:00)
Prolonged endurance running, including marathon and ultramarathon competition, is well documented to cause transient intestinal epithelial injury and increased intestinal permeability (often termed exercise-induced gastrointestinal syndrome). Splanchnic hypoperfusion, thermal strain, and mechanical stress during prolonged running compromise the gut mucosal barrier, leading to elevated permeability markers (such as the lactulose/rhamnose ratio and 51Cr-EDTA excretion) and markers of enterocyte damage (such as intestinal fatty acid-binding protein, I-FABP).
The American Gastroenterological Association formally does not recommend probiotics for most indications, except for specific conditions like pouchitis in inflammatory bowel disease.
"formally the American Gastroenterological Association does not recommend probiotics for most indications. Like we do for very specific things like pouchitis for example and inflammatory bowel disease but the data's not there." (said at 0:48:03)
The American Gastroenterological Association (AGA) published clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. In these guidelines, the AGA found insufficient evidence to recommend probiotics for most gastrointestinal indications (including Crohn's disease, ulcerative colitis, irritable bowel syndrome, and acute infectious gastroenteritis in children), making conditional recommendations supporting probiotic use only in a few narrowly defined contexts, such as pouchitis in patients with inflammatory bowel disease, the prevention of Clostridioides difficile infection in adults and children receiving antibiotics, and the prevention of necrotizing enterocolitis in preterm low-birth-weight infants.
Fecal microbiota transplantation (FMT) is highly effective as a treatment for Clostridioides difficile (C. diff) infection.
"And that works really well for conditions like C. difficile infection, which is this bacteria that can cause a really horrible infection. FMT, fecal microbiota transplant answer works really well there." (said at 0:49:40)
The claim that fecal microbiota transplantation (FMT) is highly effective for treating Clostridioides difficile (C. diff) infection is supported by high-certainty evidence. Systematic reviews and Cochrane meta-analyses of randomized clinical trials confirm that FMT leads to a large increase in resolution of recurrent C. difficile infection compared to standard antibiotic therapy (e.g., vancomycin), nearly doubling resolution rates (RR 1.92 in Cochrane review; RR 1.51 to 1.85 in recent meta-analyses) and markedly lowering recurrence rates.
Clinical trials of fecal microbiota transplantation for irritable bowel syndrome have generally failed to show strong positive patient outcomes.
"We've done so many clinical trials, and we—I mean people in this field—so many clinical trials to try to treat irritable bowel syndrome with fecal transplant, to try to treat Parkinson's disease with fecal transplant. And the outcomes aren't great. People don't actually do much better." (said at 0:50:15)
Systematic reviews, meta-analyses, and umbrella reviews of randomized controlled trials (RCTs) evaluating fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS) consistently find that FMT does not provide a reliable or robust overall clinical benefit over placebo. While some subgroup analyses suggest potential benefits depending on delivery modality (e.g., upper or lower endoscopic administration vs. oral capsules) or donor characteristics, pooled analysis of global IBS symptoms consistently shows no statistically significant superiority over placebo, supporting the speaker's statement that trials have generally shown underwhelming outcomes.
- supports: Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis … (Frontiers in cellular and infection microbiology 2022) · cited 69x in the literature
"FMT was not associated with a significant improvement in global symptom in IBS at 12 weeks in comparison with placebo (RR 0.75, 95% CI 0.43-1.31) with high heterogeneity between studies (I 2 87%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fecal Microbiota Transplantation and Health Outcomes: An Umbrella Review of Meta-Analyses … (Frontiers in cellular and infection microbiology 2022) · cited 14x in the literature
"FMT does not appear to be associated with positive outcomes in irritable bowel syndrome and metabolic syndrome." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A systematic review, pairwise meta-analysis and network meta-analysis of randomized contro… (European journal of gastroenterology & hepatology 2023) · cited 14x in the literature
"The pooled results showed no overall advantage of FMT over placebo in IBS." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta… (International journal of molecular sciences 2023) · cited 35x in the literature
"The overall symptomatology of FMT-treated IBS patients did not significantly differ from the control group (Odds Ratio (OR) = 0.99, 95% Confidence Interval (CI) 0.39-2.5)." (abstract, results, passage verified)
pubmedfull study (doi)
About one in three people with treatment-resistant constipation have pelvic floor dysfunction as the primary cause.
"And about one in three people who have what we would call constipation, they've tried different laxatives, they failed to get better with it, the issue is the pelvic floor." (said at 0:58:05)
Epidemiological and physiological studies of patients with chronic constipation who are refractory to standard initial treatments (e.g., fiber, osmotic and stimulant laxatives) consistently find that dyssynergic defecation / pelvic floor dysfunction is present in approximately 20% to 40% (roughly one in three) of referred patients, either in isolation or overlapping with slow-transit constipation.
Biofeedback physical therapy for pelvic floor dyssynergia is approximately 80% effective after two to three months of treatment.
"We treat it with a special kind of physical therapy called biofeedback. That's been shown in studies to be about 80% effective after about two to three months of physical therapy." (said at 0:59:45)
Randomized controlled trials evaluating biofeedback physical therapy for dyssynergic defecation demonstrate response and efficacy rates of approximately 70% to 80% following 3 months of treatment. For example, a randomized controlled trial comparing home-based and office-based biofeedback therapy over a 3-month intervention period reported responder rates of 70% (35/50) in the office-based biofeedback group and 68% (34/50) in the home-based biofeedback group, with significant improvements across all primary bowel and physiologic outcomes.
Short-chain fatty acids like butyrate improve the body's capacity to sense and respond to stool in the rectum.
"So I think that the beneficial short-chain fatty acids like butyrate have been studied as improving in some ways the capacity—there's two different aspects to this, but improving our capacity to sense and respond to stool that's sitting there in the rectum." (said at 1:01:02)
Human and animal studies do not support the claim that butyrate improves physiological rectal sensation or response to stool. In a double-blind, placebo-controlled crossover trial in healthy human volunteers (PMID: 19460106), rectal administration of butyrate dose-dependently decreased visceral perception, significantly reducing urge, pain, and discomfort during rectal balloon distension. In rodent models (PMID: 15940632, PMID: 22833396), rectal instillation of butyrate is widely used to induce pathological visceral hypersensitivity mimicking irritable bowel syndrome, rather than enhancing normal rectal sensory-motor reflexes.
- context: Rectal instillation of butyrate provides a novel clinically relevant model of noninflammat… (Gastroenterology 2005) · cited 171x in the literature
"Butyrate enemas induced a sustained, concentration-dependent colonic hypersensitivity and, to a lesser extent, a referred cutaneous mechanical hyperalgesia, particularly in female rats, but no macroscopic and histologic modifications of the colonic mucosa, as observed in patients with IBS." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: The effects of butyrate enemas on visceral perception in healthy volunteers. (Neurogastroenterology and motility 2009) · cited 170x in the literature
"Butyrate treatment resulted in a dose-dependent reduction of pain, urge and discomfort throughout the entire pressure range of the protocol... Colonic administration of butyrate, at physiologically relevant concentrations, dose-dependently decreases visceral sensitivity in healthy volunteers." (abstract, results and conclusions)
pubmedfull study (doi)
Approximately 7% of Americans experience fecal incontinence.
"And that's a big problem for the about 7% of Americans who deal with fecal incontinence." (said at 1:01:16)
The claim that approximately 7% to 9% of noninstitutionalized US adults experience fecal incontinence is supported by large national epidemiological data. In the National Health and Nutrition Examination Survey (NHANES) 2005–2006, the estimated prevalence of fecal incontinence (defined as accidental leakage of solid, liquid, or mucus stool at least once in the preceding month) among community-dwelling US adults aged 20 and older was 8.3% (95% CI: 7.1–9.5%) (PMID 19410574). Subsequent multi-year analyses of NHANES data (2005–2010) reported prevalence rates of 8.4% (PMID 42544354) and 9.2% (PMID 38657883). Stating "about 7%" accurately reflects the order of magnitude established in national US prevalence studies.
- supports: Fecal incontinence in US adults: epidemiology and risk factors. (Gastroenterology 2009) · cited 615x in the literature
"The estimated prevalence of FI in noninstitutionalized US adults is 8.3% (95% confidence interval, 7.1-9.5) and consists of liquid stool in 6.2%, solid stool in 1.6%, and mucus in 3.1%." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fecal Incontinence as a Marker of Multisystem Cardiopulmonary-Kidney Disease and Mortality… (Delaware journal of public health 2026)
"Among 14,731 adults (weighted mean age 46.8 years; 51.2% women), the weighted prevalence of fecal incontinence was 8.4% (95% CI, 7.8%-9.0%)." (abstract, results, passage verified)
pubmedfull study (doi)
Fiber supplements such as psyllium improve rectal sensitivity and reduce the frequency of fecal incontinence episodes.
"And they've done these studies where they found that actually just fiber supplements like psyllium can help improve that sensitivity so those episodes don't happen as often." (said at 1:01:22)
Randomized controlled trials confirm that psyllium fiber supplementation significantly reduces the frequency of fecal incontinence episodes in community-dwelling adults. However, this clinical improvement is primarily driven by psyllium's water-holding capacity and stool-bulking effect (forming a viscous stool gel that is easier to retain and evacuate) rather than a direct enhancement or repair of intrinsic rectal neuromuscular sensitivity, though a bulkier, more formed stool bolus may improve rectal mechanoreceptor perception.
Short-chain fatty acids have anti-inflammatory effects and do not sensitize visceral pain nerves.
"There's a different type of sensitivity that we sometimes talk about which is not what we think happens with short-chain fatty acids like butyrate or others, which is that if the nerve cells that sense pain and send pain signals up to the brain become more sensitized, that would be a bit of a problem. But we actually think that the short-chain fatty acids have anti-inflammatory effects and don't do that." (said at 1:01:36)
While short-chain fatty acids (SCFAs) such as butyrate possess established anti-inflammatory and epithelial barrier-supporting properties, preclinical research contradicts the assertion that they do not sensitize visceral pain nerves. Experimental models of irritable bowel syndrome demonstrate that butyrate can directly promote visceral hypersensitivity by inducing mast cell degranulation and sensitizing dorsal root ganglion (DRG) nociceptive neurons through upregulation of TRPV1 and protein kinase C pathways.
The colon operates strongly on a circadian rhythm, becoming almost completely quiescent at night and producing strong contractions in the first one to two hours after waking.
"And that is that your colon actually operates very, very strongly on a circadian rhythm. So, unlike a lot of other organs in your body, it almost goes completely quiescent at night. There's very little activity. And in those first one or two hours upon waking, the nerve cells in the gut have this, you know, circadian entrainment. It wakes up and naturally produces very strong contractions that you very rarely are getting the rest of your day." (said at 1:02:23)
Human 24-hour colonic manometry and wireless motility capsule studies confirm that colonic motor activity exhibits a distinct circadian pattern. Colonic motility and contractile activity are minimal or almost completely absent during sleep at night, and significantly increase upon morning awakening, characterized by a peak in contractility and high-amplitude propagating contractions that occur predominantly in the early morning hours and after meals.
Eating a meal, exercising, and drinking coffee all stimulate colonic contractions.
"You're going to get a little bit of it when you eat a meal. You're going to get a little bit of it if you exercise. You're going to get a little bit of it if you drink coffee." (said at 1:02:52)
Published human colonic manometry studies demonstrate that eating a meal, consuming coffee, and physical exercise (specifically during the post-exercise period) stimulate colonic motor activity and propagated contractions. In randomized physiological trials, ingestion of a meal and caffeinated coffee both significantly increase the area under the curve of colonic pressure waves and the frequency of propagated contractions. Similarly, following acute exercise, the number and amplitude of propagated colonic contractions increase, promoting colonic propulsion.
- supports: Effects of acute graded exercise on human colonic motility. (The American journal of physiology 1999) · cited 120x in the literature
"After exercise, the pressure activity reverted to baseline, but the number and amplitude of propagated waves increased (P < 0.01), whereas the simultaneous waves and cyclical events remained lower. Acute graded exercise decreases colonic phasic activity. This may offer less resistance to colonic flow, whereas the postexercise increase in propagated activity may enhance colonic propulsion." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Is coffee a colonic stimulant? (European journal of gastroenterology & hepatology 1998) · cited 137x in the literature
"Caffeinated coffee, decaffeinated coffee and meal induced more activity in the colon with a greater area under the curve of pressure waves (P < 0.01) and a greater number of propagated contractions (P < 0.05) when compared with water... Caffeinated coffee stimulates colonic motor activity. Its magnitude is similar to a meal, 60% stronger than water and 23% stronger than decaffeinated coffee." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Normal bowel movement frequency ranges from once every three days up to three times a day.
"Three times a day would be considered within the range of normal. Americans think that having a bowel movement every third day or up to three times a day could be normal." (said at 1:03:31)
Standard clinical gastroenterology criteria and population data define the normal range of bowel movement frequency as between three times per week (approximately once every two to three days) and three times per day (the common '3 and 3' rule). A study of 4,775 US adults from the National Health and Nutrition Examination Survey (NHANES) who reported normal bowel habits found that 95.9% had between 3 and 21 bowel movements per week.
Using a smartphone on the toilet can increase the risk of developing hemorrhoids.
"Stop taking your smartphone to the bathroom, guys. Not good for you. It can increase your risk of hemorrhoids." (said at 1:04:29)
Observational research supports the claim that smartphone use on the toilet is associated with an increased risk of hemorrhoids, largely driven by prolonged sitting time. A cross-sectional study of adult patients undergoing screening colonoscopy found that smartphone users spent significantly more time on the toilet and had an adjusted 46% increased risk of endoscopically confirmed hemorrhoids compared to non-users, after controlling for age, sex, BMI, physical activity, straining, and fiber intake. Because available evidence is based on observational and cross-sectional designs, the certainty of evidence is low.
- supports: Smartphone use on the toilet and the risk of hemorrhoids. (PloS one 2025) · cited 5x in the literature
"Furthermore, in a multivariate logistic regression, smartphone use on the toilet was associated with a 46% increased risk of hemorrhoids (p = 0.044) after adjusting for age, sex, BMI, exercise activity, straining and fiber intake." (abstract, results, passage verified)
pubmedfull study (doi) - context: Toilet behaviors and lifestyle factors in anorectal diseases: a cross-sectional analysis. (Frontiers in surgery 2025) · cited 3x in the literature
"They also had higher rates of constipation (>1/week: 18.9% vs. 5.7%; p < 0.001), back-to-front wiping (59.2% vs. 45.5%; p = 0.002), and prolonged toilet sitting (>20 min: 8.1% vs. 0.5%; p < 0.001)" (abstract, results, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications